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Abstract
Background: The obstetrical literature is dominated by Randomised Controlled Trials (RCTs), with the vast majority
being analysed using an intention-to-treat (ITT) approach. Whilst this approach may reflect well the consequence of
assignment to therapy and hence the ‘trialists’perspective’, it may fail to address the consequence of actually
receiving therapy (the patient’s perspective).
Discussion: This review questions the ubiquitous adherence to the ITT approach, and gives examples of where this
may have misled the maternity care professions. It gives an overview of techniques to overcome potential
deficiencies in result presentation, using method effectiveness models such as ‘Per Protocol’ (PP) or ‘As-Treated’ (AT)
that may give more accurate clinical meaning to the presentation of obstetrical results. It then proceeds to cover
the added benefits, considerations and potential pitfalls of the use of Instrumental Variable (IV) models in order to
better reflect the clinical context.
Summary: While ITT may achieve statistical purity, it frequently fails to address the true clinical or patient’s
perspective. Though more complex and potentially beset by problems of their own, alternative methods of result
presentation may better serve the latter aim. Each of the other methods may rely on untestable assumptions and
therefore it is wisest that study results are presented in multiple formats to allow for informed reader evaluation.
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Background
Intention-to-treat (ITT) analysis
In the hierarchy of statistical trials, the RCT has been on
the throne for over half a century [1]. Bradford-Hill is
credited with provision of ‘criteria’ inferring causation [2],
that have guided RCT design since 1965, though it is un-
clear whether this was his intention [3,4]. The universally
favoured method for data analysis from RCTs is ITT [5,6],
proposed for two reasons: ensuring comparable treatment
groups due to randomisation, and preventing bias in ana-
lyses resulting from post randomisation exclusions. With
ITT a solid statistical basis is said to exist for determining
the significance of any observed difference in outcome
between treatment groups [7], though all patients must be
followed according to a prespecified schedule of outcome
measurements regardless of compliance, adverse effects or
other post randomisation observations [8].
Randomisation and adherence/compliance are critical
for ITT to produce a good estimate of efficacy. Random-
isation “provides a guarantee against biased estimates of
treatment effects due to differences in the distribution of
known and unknown confounding factors” [7]. ITT pro-
duces unbiased estimates of the effects of receiving a treat-
ment only when subjects are willing to adhere to all
treatments under study and complete all planned outcome
assessments [9]. Data that are missing from randomized
patients must not bias the comparison of treatment
groups and outcome measurements must be obtained in a
like and unbiased manner for all patients [8].
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ITT can successfully provide valid estimates for the ef-
fect on outcome of assignment to therapy, though these
reflect the effect of randomisation to treatment rather
than the true effect of taking treatment [10]. Though
this works well in an ‘ideal’ statistical situation, problems
arise when ITT is applied to complex clinical scenarios.
The expression ‘treatment contamination’ may be used
for the common situation of RCT violations whether
through non-compliance (not receiving the treatment or
intervention) or crossover (switching to receive that of
the other group) [11]. Traditional implementation of
ITT assumes all subjects to be latent compliers (posses-
sing a disposition to comply) [9], which rarely occurs in
clinical practice particularly when subjects may have
strong views about which treatment they want. When
this can be ascertained before randomisation, these sub-
jects should not be included in a trial [7]. This is highly
pertinent for maternity care where patients are likely to
be highly informed. The significant non-compliance seen
in maternity studies cannot be assumed to be random
and so introduces profound selection bias where patients
chose certain treatments or protocols [12]. Thus the per-
spective of society may be that ITT analysis is appropriate
for RCTs, but this may not be appropriate from the
patient’s perspective.
In clinical practice there are frequent deviations from
‘ideal’ trial conditions, provoking compromises in RCT de-
sign to try and overcome this disconnect. Pragmatic trials
compare two treatment strategies and tend to reflect the
situation in current clinical practice, using less selected
participants and being conducted under more realistic
conditions with lower adherence to the assigned treatment
[13]. Explanatory trials concentrate on compliant patients
in order to study the biological effect of the treatment.
Many studies end up as a compromise between pragmatic
and explanatory, and large trials of long duration often
start as exploratory questions and end up as a comparison
of two strategies. Many study designs, like large simple
trials, are better described as longitudinal studies with
baseline randomisation, rather than as either pure rando-
mised or observational studies. As soon as there are devia-
tions from protocol in an RCT, then investigators are able
only to record data as if they were conducting a prospect-
ive observational study – the more deviation, the more like
an observational study it becomes [14]. This is more com-
monly seen with studies with long follow-up periods.
Often a ‘pseudo-ITT’ analysis is performed restricted to
subjects with complete data or techniques are employed
such as ‘last available observation carried forward’ or
‘complete-case’ evaluations, which are not true ITT [14].
Both of these weaker versions of ITT assume no selection
bias due to incomplete follow up.
A further alternative, when the issue is that of missing
data resulting in incomplete adherence to ITT, is the use
of (multiple) imputation analysis (MIA), a technique used
to generate plausible values for missing data, using a set of
rules for combining individual estimates and standard
errors [15]. Guidelines for combining estimates of interest
have previously been outlined [16], though previous stud-
ies have shown that despite its increasing use, it is rarely
adequately reported and potentially inappropriately ap-
plied [17]. Pitfalls of MIA include omitting outcome vari-
ables after imputation; non-normally distributed variables;
the assumption that missing data are random; computa-
tional and practical limitations [18].
Efficacy and effectiveness
Studies may aim to determine clinical efficacy (“how well
a treatment works under perfect adherence and highly
controlled conditions” [13] or the patient’s perspective on
a trial) or clinical effectiveness (“how well a treatment
works in everyday practice” [13], or society's perspective
on a trial” [13]). For clinical practice, an assessment of ef-
fectiveness that accounts for patient compliance must be
considered alongside that of efficacy [10], given the know-
ledge that a certain percentage will not comply with treat-
ment in both the clinical and research settings. Given that
some of the most critically important clinical questions
are addressed using RCTs with ITT, where there are al-
ways issues of ‘study purity’ and noncompliance, one may
wonder why ITT remains so dogmatically adhered to. A
number of reasons have been proposed including: statis-
tical simplicity; belief that all analyses not based on original
assignment are invalid; preference for simple analyses with
easily understood conclusions compared to the subjective
complexity of model based analyses; model-based analyses
often involve considerable judgement and relatively com-
plex and tedious calculations, requiring appropriate skill,
computation and software [10].
ITT does not reflect the whole complexity of patient
care and clinical events and may not appear satisfactory
unless it yields a positive result. The comparison using
ITT is regarded by most as conservative, with most com-
monly a bias towards the null hypothesis, or dilution due
to contamination of the treatment groups [10,13]. The
ITT ‘ideal’ for RCT data analysis falls far short of the ideal
of true clinical effectiveness, which is what the person
considering treatment actually needs to know. As stated in
one statistical editorial: “Life would be that simple were it
not for human beings” [19].
ITT in the obstetrical literature
In the trade-off between bias and precision, different
schools of thought exist and to date ITT has been al-
most ubiquitous in the obstetrical literature, despite its
apparent shortfalls. One of the clearest and most clinically
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detrimental examples of this is the Term Breech Trial,
where ITT contributed to conclusions that do not appear
to be clinically justified, were unsubstantiated at 2 year
maternal and neonatal follow up and have had worldwide
ramifications in maternity care [20-22]. The criticisms of
this study and its deviations from ITT are too extensive to
list here but have been detailed well in previous publica-
tions [23,24]. Also, literature regarding use of epidurals for
analgesia in labour has been clouded by a blind reliance
on ITT in RCTs, even in the face of significant crossover.
In a major RCT comparing epidural with non-epidural an-
algesia, 31% of women counselled agreed to participate,
with 42% of those agreeing in the antenatal clinic being
randomised, then 33% not receiving their intended epi-
dural and 28% from the non-epidural group receiving an
epidural [25]. The principles of randomisation and adher-
ence were not preserved in this study, yet blind belief in
the power of ITT led to the conclusion that “Despite a sig-
nificant proportion of women in each group not receiving
their allocated analgesia, a significant difference in terms
of instrumental delivery rates remained” [25]. When mul-
tiple RCTs with strict (and often flawed) ITT analysis be-
come combined into Cochrane reviews, which are then
held up to be the ‘highest possible form of evidence’ it is
no wonder that evidence-based medicine as currently pre-
sented [26] has both fans and critics [27]. ‘Clinical trialists’
still hold ITT as the statistically and therefore academically
correct method for evaluation of data in RCTs [28], though
it is clear that adherence to ‘ideal’ methodology guidelines
is suboptimal even for high-impact journals [29].
Alternatives to ITT: method-effectiveness (ME) models
When evidence-based medicine needs to be applied to real
clinical cases and to the patient’s perspective, ME models
have been proposed to be more relevant to clinical deci-
sion making than efficacy studies [10]. They may more ac-
curately reflect “human beings and the real world”, and
allow a number of behavioural evaluations [7]. Common
simple ME models include Per Protocol (PP) or As-Treated
(AT) approaches. Both make the assumption that the
probability of taking the treatment is random with respect
to all predictors of outcome [30]. Clinical trialists are sus-
picious about departures from ITT because the typically
hard issues of observational studies then surface in rando-
mized trials [19], it takes further care and skill to move be-
yond ITT and entrenched approaches are frequently hard
to shift.
A PP analysis includes all subjects who were, in retro-
spect, eligible for enrolment in the study without major
protocol violations, who received an acceptable amount of
test treatment, and who had some minimal amount of fol-
low up [31]. Selection bias comes in if the reasons that in-
fluence participants in compliance with their assigned
treatment are associated with prognostic factors [13]. It has
been recently estimated that the PP estimate (log odds ratio
(OR)) is 1.25 times the ITT estimate [32].
The ultimate goal of outcome research is to tell which
treatment or intervention is associated with the best out-
come, whether maximum benefit or minimum harm to
patients. As this may involve establishing if there is a
causal association between that treatment or intervention
and outcome, researchers concerned with the effects of
non-compliance have often used the AT approach [9],
which analyses subjects according to treatment received,
not assigned [31]. It attempts to deal with aspects of the
power calculation issue of PP analysis by using all the data,
at the price of blurring the definition of adherence to treat-
ment, but it does nothing about the causality confusion
created by the analysis-stage redefinition of treatment
groups that may create prognostically distinct populations.
If one is truly after a valid answer to the question of
‘method-effectiveness’ then it has been suggested by some
that ITT and PP will not supply a valid answer, and only
AT may do so, though at a cost [10]. Concerns regarding
AT approaches include: lost randomisation; potential for
biased results; inability to identify and account for import-
ant prognostic factors; impossibility of generalisation [33].
Unless alternative methods are considered through the
RCT process, blind adherence to ITT risks becoming a
self-fulfilling prophecy [10]. The data that would help esti-
mate method effectiveness are not gathered, and one has
little recourse but to settle for estimates of use-effective-
ness, which might, as already noted, be of little value even
for projecting use-effectiveness in the future. Unfortunately,
whilst simple PP and AT analyses may appear to reflect the
patient’s perspective more clearly, these techniques also
leave a bit to be desired. Whereas ITT most commonly suf-
fers from ‘bias towards the null’ [12,16,17], there are unpre-
dictable confounding biases in AT analysis and selection
biases in PP analysis that can go in either direction depend-
ing upon multiple factors. The estimates from these ana-
lyses can only be interpreted as the effect of treatment if
the analysis is appropriately adjusted for identifiable con-
founders [13]. This therefore means that one must adopt
some more or less elaborate “model” as simple data sum-
mary will not suffice. Models (which require untestable
assumptions) mean increased subjectivity and uncertainty
though in contrast the price for insisting on greater object-
ivity and certainty (using only ITT) is that one is less clinic-
ally relevant [10]. The clinician may be caught between
interpretations of effectiveness versus efficacy, wishing to
know the effect on their patient if they actually follow a par-
ticular treatment (efficacy), while recognising that potential
non-compliance means that measures of effectiveness may
have more meaning. It may be appropriate to include in
clinical counselling the fact that a given percentage will not
comply with a particular treatment course (influencing the
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ITT result) but that if the patient does persist that a par-
ticular effect is to be anticipated (the PP result).
Causal inference approaches and instrumental variable
models
There are a number of different causal inference approaches
that adjust for unmeasured confounders (i.e. hidden bias) in
order to improve upon the shortcomings of the method-
effectiveness models. These include inverse probability (IP)
weighting, g-estimation and instrumental variable (IV)
methods [14]. Inverse probability (IP) weighting or g-
estimation are generally used for confounding adjustment in
AT and PP analyses involving time-varying treatments and
require untestable assumptions similar to those made for
causal inference from observational studies [13]. If only se-
quential randomisation of treatment within levels of mea-
sured covariates is assumed, then IP weighting is needed. If
only a dose–response model is assumed then g-estimation
is needed [14]. If both of these assumptions are made then
either technique may be used.
The instrumental variable (IV) model, a particular form
of g-estimation that does not require measurement of any
confounders is a commonly used causal approach to esti-
mate the true trial effect [13], and may be used to obtain
for each patient a predicted probability of receiving the ex-
perimental treatment [34]. It is often regarded as a more
useful approach than ITT if method effectiveness is the
primary study goal [10]. The IV approach requires the use
of at least 1 ‘instrument’ which is a variable that is power-
ful and valid and correlates with treatment but is uncorre-
lated with unobserved determinants of the dimension of
health or clinical endpoint under study [35]. It does not
require measurement of confounders, and makes the ex-
posure of interest more or less likely (in a similar manner
to randomisation) but does not affect the outcome [36].
The IVs are assumed to mimic randomisation variables
and for each patient they obtain a predicted probability of
receiving the experimental variable [34]. It must be
stressed, however, that IV models rely on untestable
assumptions, so while they may have increased clinical val-
idity, they need to be treated with caution, and it is recom-
mended that they are not the only analysis done in an
RCT. Examples of the instrument include the randomisa-
tion method of an RCT, the cost of a treatment or regional
variations in treatment availability. In Mendelian random-
isation, genotypes may act as IVs [37]. An IV adjusted ITT
treats the RCT as an IV with treatment assignment being
the instrument, and the effect of this assignment on out-
come is adjusted by the percentage of assigned participants
who receive the treatment [11].
Whist technically more complex, a growing body of lit-
erature supports and explains the use of IV methods to de-
termine effectiveness in a number of trial situations [12,36],
correcting for non-compliance based on assumptions about
outcomes for non-compliers under both treatments [38]. A
recent publication has tabulated the strengths and weak-
nesses of the different methods of RCT analysis, proposing
use of IV to adjust for treatment contamination [11]. These
different approaches have been presented in many fields,
such as an extensive comparison of the ITT, AT and IV
approaches in psychiatry [39], though have failed to pene-
trate the obstetrical literature. Further details of the
mathematical and statistical techniques for ME assessment
as applied to longitudinal studies (g-estimation, IP and IV)
have been outlined in a recent review [14]. This review
clearly tabulates the influence of the different forms of ana-
lysis on effect estimates and 95% confidence interval in a
study on atypical antipsychotic medication. A more math-
ematical discussion of IV methods and RCTs has been pre-
sented by Dunn et al. [40].
As well as the IV approach, researchers have proposed
the use of four mutually exclusive groups using a new esti-
mator referred to as a stratified method of moments esti-
mator [7,9]. These are: compliers; always-take-experimental
treatment; never-take-experimental treatment; defiers
(always take the opposite). Estimating proportions and like-
lihoods for each of these groups may make assumptions
that hold better in randomised trials and less so in the
observational setting. Methods to estimate and overcome
bias are difficult to perform and may all need assumptions
to be made that cannot be directly measured. It is clear that
there is no single perfect method for presentation of data
from all RCTs. All model assumptions need to be articu-
lated explicitly, their validity tested against the particulars
of each trial.
Summary
Whilst RCTs provide the most scientifically and statistically
accurate method for evaluating the influence of treatment
or interventions, obstetrical studies are dominated by the
use of ITT analysis to present their data. In fact, though
ITT may correlate well with the scientific or statistical aims
of a study or of society, it frequently does not answer the
needs of the patient. Deviations from pure adherence to
the intervention under evaluation undermine the value of
ITT, and mean that patients may benefit from alternative
methods of data presentation.
In publishing RCT results, supplementation of ITT
evaluation with ‘As Treated’ or ‘Per Protocol’ starts to
provide more relevant information for patients [41], espe-
cially when there is substantial lack of adherence or loss to
follow-up, though AT and PP are relatively crude tools with
their own deficiencies. Further clinical relevance may come
from use of Instrumental Variable methods though techni-
ques such as IV rely upon the use of untestable assump-
tions, so should be treated cautiously and not used in
isolation.
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These concepts have progressed well in many disciplines
but are yet to be reflected in obstetrical medicine and ma-
ternity care, where non-compliance and treatment contam-
ination are so common. A number of well publicised trials
have misled clinical practice because of over-reliance on
ITT in the face of non-adherence after randomisation. It
therefore would be more appropriate to present results of
randomised controlled trials in multiple formats to allow
clinicians to discuss both the statistical and clinical rele-
vance of findings. It is clear that there is no single perfect
method for presentation of data from RCTs, and each
should be approached with clear knowledge of their
limitations.
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